Seres Therapeutics Stock Performance
| MCRB Stock | USD 0.76 0.02 2.32% |
The entity has a beta of 1.81, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Seres Therapeutics will likely underperform. At this point, Seres Therapeutics has a negative expected return of -0.29%. Please make sure to validate Seres Therapeutics' expected short fall, day typical price, and the relationship between the potential upside and daily balance of power , to decide if Seres Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Seres Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Global Antibiotics Market is Expected to Reach USD 59 Billion by 2030 DelveInsight | 12/05/2024 |
2 | FDA Grants Breakthrough Therapy Designation to Seres Therapeutics SER-155 for Reduction of ... | 12/09/2024 |
3 | Microbiome-Based Therapeutics Thematic Intelligence Research Report 2024 Focus on 7MM - US, France, Germany, Italy, Spain, the UK, and Japan | 01/10/2025 |
4 | Disposition of 2656 shares by Desrosier Thomas of Seres Therapeutics subject to Rule 16b-3 | 01/16/2025 |
5 | Disposition of 878 shares by Desrosier Thomas of Seres Therapeutics at 0.5407 subject to Rule 16b-3 | 01/24/2025 |
6 | Insider Trading | 02/04/2025 |
7 | Human Microbiome Market Size to Surge to 4.85 Billion by 2031, Fuelled by Research and Innovation - Exclusive Report by The Insight Partners | 02/06/2025 |
8 | Acquisition by Desrosier Thomas of 650000 shares of Seres Therapeutics at 0.782 subject to Rule 16b-3 | 02/07/2025 |
9 | Disposition of 2969 shares by Von Moltke Lisa of Seres Therapeutics subject to Rule 16b-3 | 02/14/2025 |
10 | Disposition of 4416 shares by Von Moltke Lisa of Seres Therapeutics at 0.8105 subject to Rule 16b-3 | 02/18/2025 |
11 | Seres Therapeutics, Inc. CEO Sells 10,308.06 in Stock | 02/20/2025 |
| Begin Period Cash Flow | 171.2 M |
Seres |
Seres Therapeutics Relative Risk vs. Return Landscape
If you would invest 98.00 in Seres Therapeutics on November 28, 2024 and sell it today you would lose (20.00) from holding Seres Therapeutics or give up 20.41% of portfolio value over 90 days. Seres Therapeutics is currently does not generate positive expected returns and assumes 4.8214% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Seres, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Seres Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seres Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Seres Therapeutics, and traders can use it to determine the average amount a Seres Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0594
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MCRB |
Estimated Market Risk
| 4.82 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Seres Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seres Therapeutics by adding Seres Therapeutics to a well-diversified portfolio.
Seres Therapeutics Fundamentals Growth
Seres Stock prices reflect investors' perceptions of the future prospects and financial health of Seres Therapeutics, and Seres Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seres Stock performance.
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.097 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 161.65 M | ||||
| Shares Outstanding | 170.74 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 5.64 X | ||||
| Price To Sales | 1.07 X | ||||
| Revenue | 126.33 M | ||||
| Gross Profit | (12.61 M) | ||||
| EBITDA | (94.31 M) | ||||
| Net Income | (113.72 M) | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 213.94 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (117.35 M) | ||||
| Earnings Per Share | (0.40) X | ||||
| Market Capitalization | 134.8 M | ||||
| Total Asset | 358.6 M | ||||
| Retained Earnings | (978.24 M) | ||||
| Working Capital | 76.75 M | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
About Seres Therapeutics Performance
By analyzing Seres Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Seres Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Seres Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Seres Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 13.8 K | 14.5 K | |
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | 2.92 | 3.06 |
Things to note about Seres Therapeutics performance evaluation
Checking the ongoing alerts about Seres Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Seres Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Seres Therapeutics generated a negative expected return over the last 90 days | |
| Seres Therapeutics has some characteristics of a very speculative penny stock | |
| Seres Therapeutics has high historical volatility and very poor performance | |
| Seres Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 126.33 M. Net Loss for the year was (113.72 M) with loss before overhead, payroll, taxes, and interest of (12.61 M). | |
| Seres Therapeutics currently holds about 195.8 M in cash with (117.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Seres Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Seres Therapeutics, Inc. CEO Sells 10,308.06 in Stock |
- Analyzing Seres Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seres Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Seres Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seres Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seres Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Seres Therapeutics' stock. These opinions can provide insight into Seres Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |